The National Institutes of Health (NIH) intends to award a non-competitive contract to Keyence Corporation of America for a Keyence Fluorescence Microscope system. This equipment will support the Undiagnosed Diseases Program by enabling high-sensitivity cellular experiments to analyze genetic mutations. The procurement is conducted under simplified acquisition procedures and will not exceed the simplified acquisition threshold of $350,000. Performance of services will be at the NIH facility in Bethesda, Maryland. Interested parties must submit responses by June 1, 2026, to be considered.